Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Share Purchases by Directors

23 Dec 2020 09:00

RNS Number : 6582J
Redx Pharma plc
23 December 2020
 

REDX PHARMA PLC

("Redx" or "the Company")

 

Share Purchases by Directors

 

Alderley Park, 23 December 2020 - Redx Pharma (AIM:REDX), the drug discovery and development Group focused on cancer and fibrosis, announces that it has been notified that Lisa Anson, Chief Executive Officer, has on Tuesday 22 December acquired 39,998 Redx ordinary shares at the following prices: 

 

Number of Ordinary shares purchased

Price per share (pence)

39,998

50p

 

 

Following this, Mrs Anson will hold 129,284 ordinary shares in the Company, representing 0.05 per cent. of the issued share capital.

 

 

-Ends-

 

For further information, please contact:

 

Redx Pharma Plc

T: +44 1625 469 918

Lisa Anson, Chief Executive Officer

James Mead, Chief Financial Officer

 

 

 

SPARK Advisory Partners (Nominated Advisor)

 T: +44 203 368 3550

Matt Davis/ Adam Dawes

 

 

 

WG Partners LLP (Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin

 

 

About Redx Pharma Plc 

Redx is a UK biotechnology Group whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Lisa Anson

2

Reason for notification

 

 

 

a.

Position/Status

Chief Executive

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Redx Pharma Plc

b.

LEI

213800HMS4EBXO589Y37

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary Shares of 1p each

ISIN: GB00BSNB6S51

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

39,998 at 50 pence per share

 

d.

Aggregated information

- Aggregated Volume

- Price

39,998 at 50 pence per share

e.

Date of the transaction

22/12/20

f.

Place of the transaction

Outside of trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFIFVTFVLVFII
Date   Source Headline
20th Mar 202310:38 amRNSForm 8.5 (EPT/RI)
16th Mar 20239:48 amRNSForm 8.5 (EPT/RI)
15th Mar 20234:40 pmRNSSecond Price Monitoring Extn
15th Mar 20234:35 pmRNSPrice Monitoring Extension
15th Mar 20232:05 pmRNSSecond Price Monitoring Extn
15th Mar 20232:00 pmRNSPrice Monitoring Extension
15th Mar 202310:50 amRNSStatement re: Jounce Therapeutics Press Release
14th Mar 202311:45 amRNSResult of Annual General Meeting
10th Mar 20237:00 amRNSForm 8.3 - Redx Pharma Plc
9th Mar 20234:35 pmRNSPrice Monitoring Extension
9th Mar 20232:00 pmBUSForm 8.3 - REDX PHARMA PLC
9th Mar 202311:22 amRNSForm 8 (OPD) - Jounce Therapeutics, Inc
9th Mar 202311:15 amRNSForm 8 (OPD) - Redx Pharma Plc
9th Mar 20238:34 amRNSForm 8.5 (EPT/RI)
9th Mar 20237:00 amRNSForm 8.3 - Redx Pharma plc
8th Mar 20239:05 amRNSSecond Price Monitoring Extn
8th Mar 20239:00 amRNSPrice Monitoring Extension
8th Mar 20238:38 amRNSForm 8.5 (EPT/RI)
8th Mar 20238:16 amRNSForm 8 (OPD) Jounce Therapeutics, Inc.
8th Mar 20237:00 amRNSRXC004 Topline Data From a Phase 2 Module
7th Mar 20238:30 amRNSForm 8.5 (EPT/RI)
3rd Mar 20233:08 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
2nd Mar 20238:09 amRNSForm 8.5 (EPT/RI)
1st Mar 20238:48 amRNSForm 8.5 (EPT/RI)
1st Mar 20237:00 amRNSRedx to Present at Cowen Health Care Conference
28th Feb 20236:03 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
27th Feb 20234:58 pmRNSForm 8.3 - Jounce Therapeutics, Inc
27th Feb 20234:47 pmRNSForm 8.3 - Redx Pharma plc
27th Feb 20234:36 pmRNSForm 8.3 - Jounce Therapeutics, Inc
27th Feb 20232:40 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
27th Feb 20238:48 amRNSForm 8.5 (EPT/RI)
24th Feb 20235:18 pmRNSForm 8.3 - REDX Pharma PLC
24th Feb 20233:13 pmRNSReplacement Form 8.3 - Jounce Therapeutics, Inc.
24th Feb 20232:02 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
24th Feb 202310:18 amRNSForm 8.5 (EPT/RI)
24th Feb 20237:00 amRNSForm 8.3 - Redx Pharma plc
23rd Feb 20237:15 amRNSRecommended Business Combination
23rd Feb 20237:01 amRNSRecommended Business Combination
15th Feb 20234:38 pmRNSNotice of AGM
9th Feb 20237:00 amRNSProgress Update on RXC007 Clinical Programme
23rd Jan 20237:00 amRNSRedx to Present at Wnt & ß-Catenin Pathway Summit
21st Dec 20227:00 amRNSNew Grant of Options
20th Dec 20227:00 amRNSFinal Results for the Year Ended 30 September 2022
16th Dec 20227:00 amRNSClinical Trial Agreement with MSD
13th Dec 20227:00 amRNSNotice of Preliminary Results
17th Nov 20227:00 amRNSRedx to Present Poster at IBD Nordic Conference
10th Nov 20222:00 pmRNSRXC004 Phase 2 Combination Arms to Open Enrolment
10th Nov 20227:00 amRNSRedx to Present at Jefferies London
7th Nov 20227:00 amRNSRedx Presenting at AFDD meeting
3rd Nov 20227:00 amRNSRedx to Present RXC004 Phase 1 Combination Data

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.